

Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review

Ali Salaritabar, Behrad Darvish, Farzaneh Hadjiakhoondi, Azadeh Manayi, Antoni Sureda, Seyed Fazel Nabavi, Leo R. Fitzpatrick, Seyed Mohammad Nabavi and Anupam Bishayee

Response to Reviewers

The authors of this manuscript express their sincere thanks to the Editor-in-Chief and reviewers for their critical assessment of our work. The authors have acted upon the recommendations of the Editor-in-Chief as well as reviewers which have resulted in a significant enhancement of the quality of this manuscript. All modifications incorporated in the manuscript are highlighted in red color font and described here indicating the exact location of each change, including the page and line numbers. A “point-by-point” response to the reviewers’ comments is outlined below:

Reviewer I (Reviewer’s code: 02438889)

Comment 1:

This is an informative paper with important informations for gastroenterologists with interest in IBD. Unfortunately, there is no description about the flavanols. Please add this to the manuscript.

Response:

Many thanks for your comment. The requested information on flavanols has been added to the revised manuscript (pages 21-23).

Comment 2:

The nutritional value of the flavonoids has been reported previously (Clinical Nutrition Experimental 2015).

Response:

Many thanks for your comment. The relevant information has been added to the revised manuscript (page 6, lines 11-18).

Comment 3:

Page 8: there is a typing error-interleukin-1? not interlukin. Apigenin is contained in camomile, parsley and celery.

Response:

Many thanks for your comment. The typing error has been fixed (page 9, line 1). The sentence about apigenin has been modified (page 18, lines 8 and 9).

Reviewer II (Reviewer's code: 02439579)

Comment 1:

As a potent anti-inflammatory compounds, flavonoids could be a useful alternative in the IBD management. Although most of the studies were conducted in animal models and suggested just a auxiliary function in IBD therapy, we look forward to a further in-depth clinical study to confirming the treatment effect of flavonoids in IBD.

Response:

The reviewer has made an excellent comment. We have incorporated a new section regarding clinical studies (pages 23 and 24).

Reviewer III (Reviewer's code: 00050232)

Comment 1:

The article reviews the possible uses of flavonoids in inflammatory bowel diseases. However, the authors incur a serious error in not reflecting on the positive experimental results and the flaws of these studies. Listing a series of works in the literature does not mean a revision, since the revision presupposes a critical analysis that is lacking in the present manuscript. Therefore, it does not merit publication unless there is a profound reformulation of the approach taken.

Response:

We greatly appreciate the reviewer's critical comment. We have tried our best to incorporate numerous changes to improve the quality of our work. All modifications are highlighted in red color font.

Additionally,

1. The reference list has been modified as we have added several new references. Special attention is given to conform to order of references and bibliographic style of the journal.
2. The entire manuscript has been thoroughly checked to ensure uniform style and organization.

On behalf of my coauthors, I once again express my sincere thanks to the esteemed Editor-in-Chief and erudite reviewers for their valuable suggestions and constructive input to improve the quality of this manuscript.